Specimens from 10 cases of second-generation anticoagulant rodenticide poisoning in dogs and cats were submitted to the Texas Veterinary Medical Diagnostic Laboratory during 1986 and 1987. The clinical signs most frequently observed were lethargy, dyspnea, and ventral hematomas; common necropsy findings included hemoperitoneum, hemothorax, and pulmonary hemorrhage. In the instances when histopathological examination of the tissue was done, it supported a diagnosis of coagulopathy. The presence of anticoagulants in serum or liver was confirmed by high pressure liquid chromatography, gas chromatography/mass spectrometry, or a combination of the two. Five cases of brodifacoum poisoning, 2 of bromadiolone, and 3 of diphacinone toxicity were verified. Concentrations of these rodenticides ranged from approximately 0.001 to 12 ppm.
The evolution of the warfarin-resistant rat has reof clinical signs. Three of these dogs subsequently died, sulted in the development and marketing of several more effective rodenticides. These new compounds, collectively referred to as second-generation anticoagulant rodenticides, include brodifacoum (BF), bromadiolone (BD), difenacoum, diphacinone (DC), and chlorophacinone. This group of anticoagulants has greater efficacy in warfarin-resistant rats because of increased potency and prolonged duration of action. The effectiveness of these rodenticides has led to increased usage in bait formulations available commercially, which has created a significant problem of anticoagulant toxicosis in nontarget species, principally dogs and cats?
Although some cases of suspected DC toxicity have been reported, l little information is available conceming analytical confirmation of rodenticide poisoning. The purpose of this report is to summarize the clinical signs, treatment, lesions, and analytical results of cases of second-generation anticoagulant rodenticide poisoning submitted to the Texas Veterinary Medical Diagnostic Laboratory during 1986 and 1987.
Materials and methods
Case histories. Nine canine (6 male and 3 female) and 1 feline (male) poisoning cases were studied ( Table 1) . Five of the dogs were found dead after appearing healthy hours before (2 had known exposure to DC and 1 to BD). The remaining 4 dogs and cat were presented exhibiting a variety whereas 1 dog and the cat recovered following vitamin K 1 therapy (both of these animals were known to have ingested anticoagulant bait). One dog did not respond to vitamin K 1 therapy. Clinical signs included lethargy, hematuria, dyspnea, altered gait, and ventral hematomas.
Also included in this report is the BF concentration from a case of human anticoagulant toxicity. The sampling was prompted by coagulopathies of unknown origin. In this instance, the gas chromatography/mass spectrometry (GC/MS) method designed for tissue was adapted to serum as an alternate and unequivocal means of confirmation.
Pathology procedures. All organs were examined grossly, and representative samples were fixed in 10% buffered neutral formalin. Fixed tissues were embedded in paraffin, sectioned at 6 μm, and stained with hematoxylin and eosin.
Analytical procedures. Diphacinone (DC) content of liver was determined by adapting published methods 2 to capillary or packed-column GC/MS for the analysis of benzophenone, the product of chromic acid oxidation. Ions 105 and 182 m/z were selectively monitored by GC/MS. Brodifacoum (BF) concentrations in serum were determined using high pressure liquid chromatography. 4 Brodifacoum (BF) and BD concentrations in liver were determined utilizing chromic acid oxidation methods 6 with packed-column or capillary GC/MS analysis for the common derivation product, methyl-4-bromobenzoate (MBB). Ions 214 and 216 m/z were selectively monitored. Because the derivation of BF and BD yields the same product, it was necessary to establish a history of exposure in order to differentiate between the two. If exposure could not be established, the result was expressed as BF, the product more available commercially. docardial hemorrhage, free blood in the lumen of the small intestine, atelectasis with free blood at the tracheal bifurcation, petechiations on the serosa1 surfaces of the lungs, and hemorrhagic bladder mucosa. Although histopathology was consistent with the gross findings and indicative of a coagulopathy, it was not diagnostic for anticoagulant intoxication. Lesions included diffuse interstitial cardiac hemorrhage and auricular carditis, acute centrolobular congestion and vacuolar swelling of hepatocytes, massive pulmonary edema and congestion, hemorrhages in the mucosa of the urinary tract and the serosa of the bladder wall, and hemoglobinuric nephrosis.
Analytical results. Results of analyses of sera and liver specimens for second-generation anticoagulant rodenticides are shown in Table 2 . Generally, very low concentrations of BF were detected in sera, while higher levels were found in liver. Recoveries of BF and BD from spiked liver samples were in the 60-70% range, accounting for the 55-70% yields of MBB from these compounds (unpublished data). Analysis of human serum for confirmation of ingestion of BF yielded a rather high concentration of BF as compared to those found in animals, suggesting a massive and/or recent dose.
Discussion
Second-generation anticoagulant rodenticide poisoning in nontarget species is a problem of increasing concern to both clinicians and diagnosticians. Vitamin K 1 therapy is effective, but must be continued over a 4-6-week period to avoid a recurrence of bleeding. 3 Initial diagnosis is difficult, because other causes of coagulopathy (ehrlichiosis, infectious canine hepatitis, disseminated intravascular coagulopathy, heat stroke, aflatoxicosis, inherited clotting factor deficiencies, etc.) must be considered. Clinical chemistry assays demonstrating clotting deficiencies are useful, but either a history of exposure or analytical confirmation is necessary to verify diagnosis. Presenting signs, gross lesions, and microscopic lesions are supportive and predictable, but not diagnostic. Screening methods are available for baits and feeds, 7 but no single method exists for the multiresidue determination of anticoagulants in tissues. At present, an analyst must rely on multiple and complementary methods to assay for low concentrations of various rodenticides.
Although concentrations are low, BF persists in sera for 2-3 weeks, and excretion is represented by a 2-compartment open mode1. 4 However, persistence of BF and other second-generation anticoagulants in liver has not been defined, and longer periods may be required for these compounds to be eliminated completely.
Second-generation anticoagulant rodenticides are both toxic and hazardous to nontarget species, and accurate diagnosis is essential for favorable prognosis and prevention of additional poisonings. As analytical support is expensive, time-consuming, and not widely available, often a detailed clinical history and workup are the only criteria on which to base the diagnosis. There is a need for selective and sensitive multiresidue methods to diagnose second-generation anticoagulant poisonings.
Two of the 10 cases in this report responded successfully to vitamin K 1 therapy. In both instances, the serum BF concentrations were monitored until the concentrations dropped below 0.5 ppb, at which time vitamin K 1 therapy was discontinued. These cases demonstrate the value of utilizing serum concentrations in evaluating treatment regimens. Unfortunately, only BF can be detected in sera at this time, necessitating that methods for detecting the other secondgeneration anticoagulants be developed.
